Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  ShangPharma Corp (ADR)    SHP

No quotes available
-- USD   0.00%
2014 AbbVie board ditches planned $55 billion Shire acquisition
2013 SHANGPHARMA COR : Rosen Law Firm Announces Investigation of ShangPha..
2012 SHANGPHARMA COR : ShangPharma Announces Third Quarter 2012 Results
SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

ShangPharma Corp (ADR) : ShangPharma Corporation Files 2011 Annual Report on Form 20-F

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/01/2012 | 11:05am CEST

SHANGHAI, May 1, 2012 /PRNewswire-Asia-FirstCall/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2011 with the United States Securities and Exchange Commission (the "SEC"). The annual report can be accessed on ShangPharma's website at http://ir.shangpharma.com under the Investor Relations section. ShangPharma will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of charge to its shareholders and ADS holders upon request. Requests should be directed to Ms. Lan Xie, VP of Finance and Investor Relations, by email at ir@shangpharma.com.

ABOUT SHANGPHARMA CORPORATION

ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

For further information, please contact:

ShangPharma
Ms. Lan Xie
VP of Finance and Investor Relations
Email: ir@shangpharma.com

Brunswick Group
Mr. Josh Gartner
Email: shangpharma@brunswickgroup.com
Phone: 86-10-5960-8600

SOURCE ShangPharma Corporation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHANGPHARMA CORP (ADR)
2014 AbbVie board ditches planned $55 billion Shire acquisition
2013 SHANGPHARMA CORP (ADR) : Rosen Law Firm Announces Investigation of ShangPharma C..
2012 SHANGPHARMA CORP (ADR) : ShangPharma Announces Third Quarter 2012 Results
2012 SHANGPHARMA CORP (ADR) : ShangPharma to Report Third Quarter 2012 Financial Resu..
2012 SHANGPHARMA CORP (ADR) : ShangPharma and Harbour Antibodies Announce Licensing A..
2012 SHANGPHARMA CORP (ADR) : ShangPharma Announces Second Quarter 2012 Results
2012 SHANGPHARMA CORP (ADR) : ShangPharma to Report Second Quarter 2012 Financial Res..
2012 SHANGPHARMA CORP (ADR) : ShangPharma Independent Committee Appoints Financial Ad..
2012 SHANGPHARMA CORP (ADR) : ShangPharma Independent Committee Appoints Chairman and..
2012DJU.S. HOT STOCK FUTURES : Hot stocks to watch
More news
Sector news : Biotechnology & Medical Research - NEC
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/12DJAmgen Biosimilar Gets Thumbs-Up From FDA Panel
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
07/09DJCorrections & Amplifications -- WSJ
07/08DJAMGEN : Theranos Dealt Blow as Holmes Is Banned From -2-
More sector news : Biotechnology & Medical Research - NEC